We push the boundaries of science and imagination to discover and develop innovative medicines for patients Learn More

The Science of Saving Lives

about-pic-1_1
about-pic-2_1
about-pic-3
about-pic-4_1

About

Sensei Biotherapeutics is developing a pipeline of medicines designed to fulfill the substantial potential of the immune system to defeat cancer and other diseases.

Driven by world class scientists and an entrepreneurial culture focused on rigorous science, innovative treatments, and data-driven decision making, we discover and develop medicines that have the potential to alter the treatment landscape and contribute value to patients and society. We are utilizing two unique drug discovery approaches. The first approach is our ImmunoPhage™️ platform, that generates powerful, self-adjuvanted, and specific immune responses. Our most advanced ImmunoPhage™️ program, SNS-301, is currently enrolling patients in a Phase 1/2 clinical trial, as a potential treatment for squamous cell carcinoma of the head and neck (SCCHN). An additional ImmunoPhage™️ program includes SNS-401, an ImmunoPhage™️ cocktail for the treatment of Merkel Cell Carcinoma. We plan to submit an investigation new drug submission in the first half of 2022 for this product candidate. The second approach is our monoclonal antibody (mAb) and nanobody platform, which are comprised of unique human monoclonal antibodies and alpaca-derived nanobodies that are selectively active in the tumor microenvironment. SNS-VISTA is our most advanced antibody-based therapeutic targeting an immune checkpoint gene that inhibits anti-tumor immune responses called V-domain Ig suppressor of T cell activation (VISTA). IND-enabling studies for SNS-VISTA are expected by the end of 2021. Through the targeted use of these programs, we believe we can further enhance therapeutic activity.

Senior
Leadership

Driven by world class scientists and an entrepreneurial culture, we have brought together leaders with deep expertise in the core disciplines of biology, immunology, and oncology along with a highly accomplished team of life science business leaders.

Marie-Louise Fjaellskog, M.D., Ph.D.

Chief Medical Officer

John K. Celebi, M.B.A.

President and CEO

Robert Pierce, M.D.

Chief Scientific Officer

In the News

Sorting:
Sort Ascending
  • Sensei Biotherapeutics Presents First Preclinical Data on SNS-723 CAR-T and Long-Term Results on SNS-301 Data at the 2019 American Association for Cancer Research (AACR) Annual Meeting

    -Multiple SNS-723 CAR constructs demonstrated significant expression of ASPH-specific CARs on T-cells, dose-dependent cell killing, and cytokine responses -Dose-dependent and durable ASPH-specific immune responses observed in patients dosed with SNS-301, consistent with earlier findingsRead More

  • Sensei Biotherapeutics Announces Formation of New Immuno-Oncology Advisory Board

    - Company brings together world-recognized leaders in immunobiology, cancer biology, and clinical and translational medicine - GAITHERSBURG, Md.--( BUSINESS WIRE )--Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, todayRead More

  • Sensei Biotherapeutics Appoints Former Head of the National Cancer Institute, Samuel Broder, M.D. to its Board of Directors

    GAITHERSBURG, Md.--( BUSINESS WIRE )--Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, today announced the appointment of Samuel Broder, M.D. to its Board of Directors. Dr. Broder is an accomplished leader in the oncology spaceRead More

In the News

Sorting:
Sort Ascending
  • Sensei Biotherapeutics Presents First Preclinical Data on SNS-723 CAR-T and Long-Term Results on SNS-301 Data at the 2019 American Association for Cancer Research (AACR) Annual Meeting

    -Multiple SNS-723 CAR constructs demonstrated significant expression of ASPH-specific CARs on T-cells, dose-dependent cell killing, and cytokine responses -Dose-dependent and durable ASPH-specific immune responses observed in patients dosed with SNS-301, consistent with earlier findingsRead More

  • Sensei Biotherapeutics Announces Formation of New Immuno-Oncology Advisory Board

    - Company brings together world-recognized leaders in immunobiology, cancer biology, and clinical and translational medicine - GAITHERSBURG, Md.--( BUSINESS WIRE )--Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, todayRead More

  • Sensei Biotherapeutics Appoints Former Head of the National Cancer Institute, Samuel Broder, M.D. to its Board of Directors

    GAITHERSBURG, Md.--( BUSINESS WIRE )--Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, today announced the appointment of Samuel Broder, M.D. to its Board of Directors. Dr. Broder is an accomplished leader in the oncology spaceRead More

Signup For Update

sign up for newsletter and get the latest update